Personalized treatment to help people with cancer quit smoking and live longer
Precision Treatment to Promote Smoking Cessation and Survival in Oncology Patients
We will test whether personalized tobacco treatment using clinical, genetic, and biomarker information helps cancer patients who smoke quit and use cessation medications more than usual care.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 112 (estimated) |
| Ages | 18 Years to 89 Years |
| Sex | All |
| Sponsor | Washington University School of Medicine Academic / other |
| Locations | 1 site (St Louis, Missouri) |
| Trial ID | NCT07166120 on ClinicalTrials.gov |
What this trial studies
This is a multilevel precision tobacco treatment program (PrecisionTx-Onc) that gives personalized risk, benefit, and medication recommendations to clinicians and patients using clinical, genetic, and biomarker data. The intervention is compared to usual care in a 2-arm cluster randomized trial of 16 clinicians and about 96 patients (roughly six patients per clinician) with 1:1 allocation. Primary outcomes include patient receipt of tobacco treatment, medication use, and smoking abstinence measured at six months, along with mechanistic and implementation outcomes. The study is embedded in oncology/hematology clinics and was developed with input from both patients and providers.
Who should consider this trial
Good fit: Adult oncology clinic patients aged 18 to 89 who currently smoke about five or more cigarettes per day, can speak English, and are willing to consider medication to help reduce craving or smoking.
Not a fit: People already using smoking-cessation medication, those with contraindications to combination nicotine replacement therapy or varenicline (including pregnancy or certain cardiac problems), non-English speakers, or those unwilling to try medications may not benefit.
Why it matters
Potential benefit: If successful, patients could get better-matched cessation medications and more clinician support, increasing quit rates and potentially improving survival.
How similar studies have performed: Some prior work suggests precision-guided smoking treatments can improve medication matching and quit outcomes, but applying a multilevel precision intervention specifically in oncology clinics is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Eligibility Criteria for Clinicians: * Clinician from participating oncology/hematology clinic * At least 18 years of age * Can speak and understand English Inclusion Criteria for Patients: * Patient at participating clinic * Age 18-89 years * Current smoking (average cigarettes per day ≥5) * Can speak and understand English * Willing to consider medication to help reduce craving or smoking such as nicotine patch, lozenge, or varenicline Exclusion Criteria for Patients: * Active use of smoking cessation medication (within the past 30 days) * Receipt of smoking cessation medication or prescription for smoking cessation medication (within the past 30 days) * Having a contradiction for cNRT or varenicline (allergic reactions, current cardiac problems, pregnancy) * Patients who were deemed by the investigator to be ineligible for participation in the trial
Where this trial is running
St Louis, Missouri
- Washington University School of Medicine — St Louis, Missouri, United States (Recruiting)
Study contacts
- Principal investigator: Li-Shiun Chen, ScD, M.D., MPH — Washington University School of Medicine
- Study coordinator: Li-Shiun Chen, ScD, M.D., MPH
- Email: li-shiun@wustl.edu
- Phone: 314-362-3932
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.